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Patients with hypertrophic cardiomyopathy (HCM) are prone
to arrhythmias and sudden death. A subset have evidence of
obstruction to left ventricular (LV) outflow caused by contrac-
tion of the hypertrophied proximal interventricular septum and
by systolic anterior motion of the mitral valve (SAM). LV
outflow obstruction may be evident under basal conditions or
may develop only after provocation maneuvers, such as the
Valsalva maneuver and reduction of preload or afterload.
Severe SAM is almost invariably associated with functional
mitral regurgitation. In addition to the hemodynamic burden
imposed by the LV outflow obstruction, other interacting
abnormalities often coexist that may also contribute to dis-
abling symptoms: impaired LV diastolic and systolic dysfunc-
tion, myocardial ischemia and arrhythmias. Occasionally, the
level of obstruction is at mid-LV cavity or, in more complex
forms, is present at both LV outflow tract and midcavity sites.
In addition, there may be obstruction to RV outflow.
LV outflow obstruction is an important determinant of
clinical outcome. Therapies that reduce the intracavitary pres-
sure gradients improve myocardial perfusion, LV filling pres-
sures and symptoms. Patients are initially treated with beta-
adrenergic blocking agents, verapamil or disopyramide, alone
or in combination. Traditionally, LV myotomy and myectomy
(LVMM) or mitral valve replacement (MVR) has been pro-
posed for obstructive HCM associated with drug-refractory
symptoms. The results of cardiac surgery have improved, but
LVMM is a major operation with significant morbidity and
mortality. Chemical septal ablation and fully automatic (DDD)
pacing are two recent examples of the continuing search for
alternative therapeutic strategies to lessen symptoms by reduc-
ing the LV outflow obstruction.
Chemical septal ablation. Chemical septal ablation in-
volves infusion of ethanol through an angioplasty catheter into
one or more septal perforator branches of the left anterior
descending coronary artery (1–5). The aim is to infarct and
thereby thin the part of the proximal interventricular septum
that is implicated in the LV outflow obstruction. The report by
Seggewiss et al. (5) in this issue of the Journal provides further
evidence that this procedure may reduce LV pressure gradi-
ents, reduce symptoms and increase exercise tolerance; how-
ever, there are concerns about this therapy (6,7).
Early complications. Ethanol-induced septal infarction has
been complicated by in-hospital conduction abnormalities and
heart block requiring pacemaker implantation, ventricular
arrhythmias and death (Table 1).
Potential late complications. The late results of this proce-
dure are unknown. There are two potentially adverse long-
term consequences of myocardial septal infarction:
1. Increased incidence of bradyarrhythmias and tachyar-
rhythmias may result. His-Purkinje conduction abnormalities
are common in HCM and can progress and cause sudden death
(8,9). Further conduction abnormalities resulting from chem-
ical septal ablation may increase the tendency to develop
complete heart block. Patients with HCM are also prone to
ventricular arrhythmias, probably on the basis of myocardial
fiber disarray and fibrosis. For example, nonsustained ventric-
ular tachycardia may be recorded in 25% to 30% of patients
after several days of ambulatory Holter monitoring. A large
septal infarction may predispose patients to sustained malig-
nant ventricular arrhythmias by creating an additional arrhyth-
mogenic ventricular substrate.
2. Aggravation of LV dysfunction may result. It is worth
noting that HCM is a primary disease of the myocardium.
There is increasing evidence that the LV hypertrophy in HCM
is secondary and compensates for intrinsically reduced LV
function. HCM is caused by missense mutations of one of
several sarcomeric proteins that impair contraction. For exam-
ple, at the level of the molecular motor, mutant beta-myosins
translocate fluorescently labeled actin at lower velocities in an
in vitro motility assay (10). Also, single-skinned slow skeletal
(soleus muscle) myofibers, demonstrated to contain the car-
diac mutant beta-myosin, have impaired mechanical properties
and generate reduced isometric force and unloaded shortening
velocity and power (11). Furthermore, tagging magnetic reso-
nance imaging studies have also demonstrated regional impair-
ment of LV wall contraction (12). The marked LV wall
thickness reduces wall tension and augments LV systolic
function in the short and medium term. The low wall stresses
and small LV volumes create an impression of a hypercontrac-
tile LV that masks the underlying impaired systolic LV func-
tion. In the long term, myocyte necrosis, fibrosis, myocellular
energy depletion and diastolic dysfunction develop and result
in cardiac failure. In some patients the disease progresses to
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LV wall thinning and overt heart failure requiring heart
transplantation.
It is possible that as with LVMM, the LV dysfunction due
to the chemical septal ablation is compensated for by a
reduced LV work load that results from the lower LV systolic
pressures and relief of the LV outflow obstruction. It is
therefore to be determined whether, in the long term, the
reduction in LV pressure gradients translates into reduced LV
filling pressures and improved myocardial perfusion. For the
present, it is uncertain whether it is prudent to cause large
myocardial infarctions in a disease in which the primary
problem is LV contractility (6,7).
DDD pacing. To date, more than a dozen centers world-
wide have demonstrated the ability of DDD pacemakers to
reduce LV outflow obstruction and associated mitral regurgi-
tation, reduce drug-refractory symptoms and improve exercise
performance (Table 2) (13–29). These reports include a Eu-
ropean double-blind, randomized study of DDD pacing versus
placebo AAI pacing involving 83 patients (Pacing in Cardio-
myopathy [PIC] study [27]). In that study, early reprogram-
ming from AAI to DDD pacing became necessary in 14
patients because of persistent or recurring symptoms. At the
end of the study, DDD pacing was preferred by 90% of
patients.
DDD pacing reduces LV outflow obstruction through both
acute and chronic cardiac changes. Acutely, RV pacing may
cause paradoxic or diminished inward movement of the ven-
tricular septum that would increase systolic LV outflow tract
dimensions and hence reduce LV outflow blood velocities (16),
which would reduce SAM, further diminishing LV outflow
tract obstruction and mitral regurgitation. However, this mech-
anism cannot explain all the pacing-induced hemodynamic
changes. This view is reinforced by the ability of DDD pacing
to reduce LV outflow obstruction in patients with LBBB and
during inadvertent LV apical pacing (18,30). The hemody-
namic outcome is better when pacing is performed from the
right ventricular (RV) apex compared with the RV midseptum
or RV outflow tract (31). Hence, the paced asynchronous
apical/base ventricular contraction may play an important part
in acutely opening the LV outflow tract at the level of the
mitral valve during systole. Prolonged pacing alters electrical
and hemodynamic properties of the myocardium (32). Repeat
cardiac catheterization studies during the course of 1 year after
implantation of a DDD pacemaker demonstrate progressive
reduction in LV outflow gradients (18,33). The altered hemo-
dynamic status is also observed during sinus rhythm when
DDD pacing is temporarily discontinued and cannot be ex-
plained on the basis of alterations in heart rate or cardiac
output. Long-term DDD pacing is also associated with less
angina, fewer LV segments with reversible perfusion defects
and less apparent cavity dilation (34). Part of the stimulus for
LV hypertrophy may be the elevated LV systolic and end-
diastolic pressures, and the reduction in LV pressures may be
associated with LV remodeling (18,29,35). These unexpected
adaptive changes probably contribute importantly to the suc-
cess of DDD pacemaker therapy in obstructive HCM. Also,
due to the hemodynamic changes that occur after prolonged
pacing, the correlation between the acute and chronic changes
is not sufficiently good to allow prediction of which individual
patient will or will not benefit from DDD pacing.
DDD pacing may be effective in patients with rest or
provokable obstructive HCM, patients with LBBB and patients
who have failed to derive benefit from a previous LVMM (18).
The hemodynamic benefits of DDD pacing in obstructive
HCM are maintained after 5 years of therapy (Table 3) (36).
Although short-term RV pacing may aggravate indexes of LV
diastolic function (37), over the long term, LV function is well
preserved, and there is a reduction in LV filling pressures (18).
Abbreviations and Acronyms
AV 5 atrioventricular
DDD 5 fully automatic pacing
HCM 5 hypertrophic cardiomyopathy
LBBB 5 left bundle branch block
LV 5 left ventricular
LVMM 5 left ventricular myotomy and myectomy
MVR 5 mitral valve replacement
RF 5 radiofrequency
RV 5 right ventricular
SAM 5 systolic anterior motion of the mitral valve
Table 1. Experience With Chemical Septal Ablation for Obstructive Hypertrophic Cardiomyopathy
Study (ref no.) Year
No. of
Pts
Duration of
FU (mo)
LVOT Gradient
(mm Hg) NYHA Functional Class Complications [no. (%) of pts]
Baseline FU Baseline FU Death Heart Block VT/VF
Gietzen et al. (2) 1996 7 0.5 58 6 51* 13 6 11* 3.0 — 0 0 0
(Bielefeld, Germany)
Knight et al. (4) 1997 18 4.0 6 2.2* 68† 22† 2.6 6 0.6* 1.1 6 0.8* 0 4‡ 2
(UK and Germany)
Seggewiss et al. (5) 1997 24 3 62 6 30* 19 6 21* 2.8 6 0.6* 1.4 6 1.1* 1 (4%) 5 (20%) 2
(Bad-Oeynhausen,
Germany)
*Mean value 6 SD. †Estimated by echocardiography. ‡Transient. FU 5 follow up; LVOT 5 left ventricular outflow tract; NYHA 5 New York Heart Association;
Pts 5 patients; ref 5 reference; VT/VF 5 ventricular tachycardia/ventricular fibrillation; — 5 no data.
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The prognosis after DDD pacing appears to be similar to that
in patients with HCM with mild or no symptoms.
There are several causes of failure of this therapy (Table 4).
The ability of DDD pacing to relieve LV outflow obstruction is
critically dependent on proper pacemaker programming and
ensuring ventricular capture without unduly interfering with
left atrial emptying. About 60% of patients require drug
therapy for residual cardiac symptoms and systemic hyperten-
sion and to optimize ventricular pre-excitation, improve left
atrial emptying, reduce LV diastolic dysfunction, and manage
atrial and ventricular arrhythmias. In one study (38), radiofre-
quency (RF) ablation of the atrioventricular (AV) node was
performed in 18% of patients to improve ventricular pre-
excitation. RF ablation of the AV node plus implantation of
dual-mode switching devices may also be used to treat obstruc-
tive HCM complicated by atrial fibrillation (Fananapazir L, et
al., unpublished observations).
Cardiac surgery: LVMM and MVR. Few centers have
adequate experience with LVMM or Morrow’s procedure. For
the procedure to be successful, enough muscle must be re-
moved from the proximal septum to sufficiently widen the LV
outflow tract. The trough must also extend beyond the point of
the mitral valve leaflet–septal coaptation. There has not been
any randomized evaluation of LVMM, which is performed
mostly in patients in New York Heart Association functional
class III or IV despite trials of verapamil, beta-blockers or
disopyramide, alone or in combination, although some series
include patients with no or minimal symptoms. The procedure
results in elimination or amelioration of symptoms in ;70% of
patients. The operative mortality has declined in recent years
(Table 5) (39–47), but there is a 1% to 2% cumulative annual
mortality. The procedure often causes LBBB, and ;5% of
patients require permanent pacemakers because of heart
block. Other important complications include ventricular sep-
tal defect, a second operation to relieve residual LV outflow
obstruction, arrhythmias, aortic regurgitation and progressive
LV dysfunction. Operative mortality rates are significantly
higher when LVMM is combined with another cardiac surgical
Table 2. Some of the Worldwide Experience With DDD Pacing for Obstructive Hypertrophic Cardiomyopathy in Adults
Study (ref no.) Year Location
No. of
Pts
Duration of
FU (mo)
LVOT Gradient
(mm Hg) NYHA Functional Class
Baseline FU Baseline FU
Hassenstein et al. (13) 1975 Germany 4 56% reduction
McDonald et al. (14) 1988 Ireland 11 24 43 ? 3.3 1.54
Jeanrenaud et al. (15) 1992 Switzerland 13 62 82 6 42* 47 6 34* 3.0 1–2
Fananapazir et al. (17) 1992 U.S. (NIH) 84† 16 6 4* 96 6 41*‡ 27 6 31*‡ 3.2 6 0.5* 1.6 6 0.6*
Fananapazir et al. (18) 1994
Tascon et al. (19) 1994 Spain 9 10 6 6* 105 6 32* 40 6 35* 3.7 6 1.2* 1.2 6 0.4*
Umman et al. (20) 1995 Turkey 5 2.2 6 3* 78 6 20* 42 6 17* 2.6 6 0.5* 1.6 6 0.5*
Yusvinkevich et al. (21) 1995 Russia 17 3.0 73 6 39* 38 6 34* 3.3 6 0.9* 1.6 6 1.1*
Gras et al. (22) 1995 France 32 34 6 14* 112 6 31* 19 6 12* 3.2 6 0.5* 1.4 6 0.5*
Nishimura et al. (23) 1995 U.S. (Mayo Clinic) 19 3.0 77 6 61* 42 6 26* 2.9 6 0.4* 2.4 6 0.7*
Ghambir et al. (24) 1995 India 12 94 6 29* 39 6 15* 3.0
Gadler et al. (25) 1996 Sweden 45§ 3.0 87 6 37*‡ 23 6 16*‡ 3.0 6 0.6* 1.8 6 0.6*
Slade et al. (26) 1996 England, France, Poland 56 11 6 11* 78 6 31* 38 6 24* 2.8 6 0.5* 1.7 6 0.7*
Kappenberger et al. (27) 1996 12 European centers 82 3 59 6 36* 30 6 25* Less by 0.7
Sakai et al. (28) 1996 Japan 13 6.0 96 17
Iliou et al. (29) 1996 France 11 12 38.8 6 19.3* 14.4 6 6.5* 3.0 6 0.4* 2.3 6 0.3*
*Mean value 6 SD. †Seventy-four patients with rest obstruction and 10 with provokable obstruction only. ‡Gradients in patients with rest obstruction only.
§Twenty-five patients with rest obstruction and 20 with provokable obstruction only. NIH 5 National Institutes of Health; other abbreviations as in Table 1.
Table 3. Long-Term Results of DDD Pacing in 18 Patients With Obstructive Hypertrophic Cardiomyopathy*
NYHA
Functional
Class
Cardiac Output
(liters/min)
PCWP
(mm Hg)
LV SBP
(mm Hg)
Aortic Pulse
Pressure
(mm Hg)
LVOT
Gradient
LVEDP
(mm Hg)
Baseline (NSR) 3.2 6 0.4 5.3 6 1.1 15 6 7 185 6 47 46 6 13 77 6 52 19 6 7
Initial follow-up
DDD 1.2 6 0.4* 5.3 6 1.0 13 6 6 140 6 28* 53 6 19 19 6 23*
NSR 5.0 6 0.8 13 6 5 145 6 29* 52 6 21 33 6 34* 17 6 7
5-yr follow-up
DDD 1.8 6 0.7* 4.9 6 0.9 13 6 5 142 6 27* 61 6 20* 14 6 25*
NSR 5.0 6 0.8 12 6 4 149 6 33 59 6 23 24 6 30* 17 6 6
*p , 0.01 versus baseline. Data presented are mean value 6 SD. DDD 5 fully automatic pacing; LVEDP 5 left ventricular end-diastolic pressure; LV SBP 5 left
ventricular systolic blood pressure; NSR 5 normal sinus rhythm; PCWP 5 pulmonary capillary wedge pressure; other abbreviations as in Table 1.
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procedure. MVR is also very effective in relieving LV outflow
obstruction because it eliminates SAM (48). However, the
problems associated with management of a mitral prosthesis,
including the need for long-term anticoagulation, demand that
this procedure be limited to patients with independent mitral
valve disease (48).
Summary. Selection of patients and individualizing therapy.
No therapy is curative or has been shown to improve prognosis.
Treatment in adult patients with HCM should therefore be
considered only in symptomatic patients. Initially, it should
consist of empiric pharmacotherapy. Patients with obstructive
HCM who fail to benefit from drug therapy should be evalu-
ated for DDD pacing or chemical septal ablation, preferably as
part of a randomized, prospective study. It should be noted
that patients who fail to benefit from one of these two
therapies may be considered for the alternative treatment
modality or for cardiac surgery. Patients with a relatively thin
interventricular septal thickness (,18 mm) and midcavity LV
obstruction are not suitable for chemical septal ablation or
LVMM. Cardiac surgery is particularly indicated if additional
operative procedures, such as coronary artery bypass graft
surgery, are being considered (Table 6).
Need for rigorous studies. Unfortunately, few studies assess-
ing the efficacy of these therapies provide complete hemody-
namic data. Whenever possible, studies should be without all
drugs that affect LV outflow pressure gradients. The LV
outflow obstruction in HCM is dynamic and hence may vary
markedly under different circumstances. LV outflow pressure
gradient is therefore a good indicator of severity of LV outflow
obstruction only if other related variable remain constant (e.g.,
heart rate, cardiac output and LV filling pressures). An
increase in arterial pulse pressure is also a good indication of
reduction of LV outflow obstruction. It is probably preferable
to report separately the findings in patients with provokable
and rest LV outflow obstruction. Provocation maneuvers, such
as the Valsalva maneuver and premature ventricular extrasys-
tolic beats, provide variable results. The best test of severity of
provokable LV outflow obstruction is probably measurement
Table 4. Possible Explanations for Failure of DDD Pacing to
Reduce Symptoms or Relieve Left Ventricular Obstruction
Inappropriate pacemaker programming
Inadequate ventricular pre-excitation: AV delay too long
Interference with left atrial emptying: AV delay too short
Inadequate duration of trial of pacemaker therapy
Other associated abnormalities
Proximal or high septal ventricular lead position
Aberrant papillary muscle obstructing LV outflow
Primary mitral valve regurgitation*
Midcavity LV obstruction†
Atrial and/or ventricular tachyarrhythmias
LV diastolic dysfunction
Myocardial ischemia
Inappropriate drug therapy
Diuretic drugs
Vasodilators
Inotropic drugs
Symptoms unrelated to LV outflow obstruction
LV diastolic dysfunction
Arrhythmias
Myocardial ischemia
*Mitral valve regurgitation in obstructive hypertrophic cardiomyopathy may
be primary and difficult to distinguish from severe mitral regurgitation due to
septal anterior motion of the mitral valve when the outflow obstruction is
relieved. †Pacing may relieve midcavity obstruction if the ventricular lead is
placed below the level of the obstruction. AV 5 atrioventricular; LV 5 left
ventricular.
Table 5. Experience With Left Ventricular Myotomy and Myectomy for Obstructive Hypertrophic Cardiomyopathy
Study (ref no.) Year
No. of
Pts
Duration of
FU (yr)
LVOT Gradient NYHA Functional Class Mortality Rate
Baseline FU Baseline FU Early Late
Maron et al. (39) 1978 124 5.2 3.0 1.3 8% 1.8%
McIntosh and Maron (40) 1988 11.5 80 6 45* 16 6 28* 2.2%
(NIH, 1960–1975)
Krajcer et al. (41) 1989 127 9.9 6 4.6* 69 6 41* 10 6 22* 3.2 2.1 4.7% 0.7%
(Houston, TX, 1963–1985)
Delahaye et al. (42) 1993 20 5.7 6 0.7* 84 6 31* 21 6 21* 2.9 6 0.6* 1.6 6 0.6* 5% 1.1%†
(Lyon, 1974–1991)
Schulte et al. (43) 1993 272 8.2 54 6 3* 9 6 1*‡ 3.0 6 0.3* 1.6 6 0.6* 2.9% 1.2%†
(Germany, 1963–1991)
Weerasena et al. (44) 1994 145 5 — — — 1–2 0.7% 1.6%§
(Toronto, 1971–1993)
Heric et al. (45) 1995 95 3.7 6 0.33* 93 21\ 2.8 6 0.5* 1.36 6 0.62* 4% 2.1%†
(Cleveland Clinic, 1975–1993)
Robbins and Stinson (46) 1996 131 6.1 6 4.8* 66.8 6 39*¶ 8.2 6 14*¶ 2.8 — 2.3% 4.6%†
(Stanford, CA, 1972–1994)
McCully et al. (47) 1996 45 2.4 6 1.7* 62.9 6 42 — 3.15 6 0.54* 1.6 6 0.69*† 0% 1.6%†
(Mayo Clinic, 1986–1992)
*Mean value 6 SD. †Includes total mortality for all patients, including procedures additional to myectomy. ‡Intraoperative recordings. §Includes operative
mortality. \Based on catheterization or echocardiographic data and was maximal gradient (rest or provoked). ¶Echocardiographic data. Abbreviations as in Table 1.
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of LV pressure gradients induced by isoproterenol at the same
increased heart rate.
Cardiac catheterization is essential for accurate assessment
of results of therapy because echocardiography does not
provide information about cardiac output and LV filling
pressures, which are critical to an accurate estimation of
severity of LV outflow obstruction. Furthermore, although
Doppler interrogation of LV outflow velocities provides a
reasonable estimate of LV outflow pressure gradients, echo-
cardiographic and cardiac catheterization measurements of
LV outflow pressure gradients should be analyzed separately.
Perhaps the time has arrived for prospective, randomized
studies comparing the effects of DDD pacing and chemical
ablation of the septum on symptoms, exercise performance,
spontaneous arrhythmias and arrhythmias detected during
electrophysiologic studies, myocardial perfusion abnormalities,
LV systolic and diastolic function and cardiac remodeling.
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